Home > Search Results

Results: 1 to 20 of 128

Dolutegravir / Abacavir / Lamivudine -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of this report was to assess the added benefit of the drug combination dolutegravir / abacavir / lamivudine (DTG / ABC / 3TC) compared with the appropriate comparator therapy (ACT) in adults and adolescents above 12 years of age infected with human immunodeficiency virus (HIV).

Institute for Quality and Efficiency in Health Care (IQWiG).

Version: December 18, 2014

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is among the most common types of cancer. Surgical resection is considered the first‐line therapy in early HCC, relapse is the main postoperative problem. A large proportion of participants with HCC have hepatitis B virus infection. Lamivudine with or without adefovir dipivoxil are considered effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver, and are widely used as adjuvant therapy postoperatively. As yet, there is no evidence that lamivudine with or without adefovir dipivoxil is effective or not for postoperative HCC. The authors found no randomised clinical trials that could be included in the present review. Hence, no conclusions could be drawn.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults

People infected with HIV/AIDS require an antiretroviral regimen that works well, has good activity against the virus, has few adverse effects (unintended negative effects of the drug) and that does not interact with other drugs. The regimen of nevirapine, stavudine and lamivudine is widely used as first‐line therapy, and is recommended as such by the World Health Organization for so‐called low‐resource countries (in other words, for poor countries). This review identified two randomised controlled trials that assessed the efficacy of this drug combination. One trial was a small single‐centre Australian trial of 70 participants, whereas the other trial was a large, multicentre trial, conducted in 14 countries, of 1,216 participants. In both trials over 60% of participants were male and none had been on previous antiretroviral treatment. As one trial was very small, we cannot be sure of its results. The main findings therefore come from the much larger trial. This trial compared the combination of nevirapine, stavudine and lamivudine with the combination of efavirenz, stavudine and lamivudine, and found that participants had similar treatment outcomes on either combination. It also found that taking nevirapine once a day with twice daily stavudine and lamivudine worked as well as taking nevirapine twice a day in combination with twice daily stavudine and lamivudine. Nevirapine did appear to cause more adverse effects compared with efavirenz, but additional assessment of this is necessary to be more certain.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

Co‐formulated abacavir‐lamivudine‐zidovudine for treating HIV infection and AIDS

The primary objective of this review was to evaluate the antiviral efficacy of co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection. The secondary objectives were to evaluate the safety and tolerability of the triple drug combination. We identified 15 potentially eligible studies, four of which met our inclusion criteria. Our findings indicate that co‐formulated abacavir‐lamivudine‐zidovudine remains a viable option for initiating antiretroviral therapy, especially in HIV‐infected patients with pre‐existing hyperlipidaemia and those who do not tolerate ritonavir.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Combination therapy with lamivudine and HBIG versus lamivudine monotherapy in prevention of hepatitis B virus recurrence after liver transplantation: a systematic review

Bibliographic details: Jiang Z, Jiang J.  Combination therapy with lamivudine and HBIG versus lamivudine monotherapy in prevention of hepatitis B virus recurrence after liver transplantation: a systematic review. Chinese Journal of Evidence-Based Medicine 2010; 10(8): 864-871

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Lamivudine versus lamivudine-thymosin alpha-1 combination therapy for HBeAg positive chronic hepatitis B: a systematic review

Bibliographic details: Hu H B, Xu T, Cheng K, Su N, Tang Y.  Lamivudine versus lamivudine-thymosin alpha-1 combination therapy for HBeAg positive chronic hepatitis B: a systematic review. Chinese Journal of Evidence-Based Medicine 2009; 9(8): 904-909

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Interferon-[alpha] combined with lamivudine for children with hepatiitis B: a meta-analysis

Bibliographic details: Jian N, Fang ZQ, Chen QM, Chen QF.  Interferon-[alpha] combined with lamivudine for children with hepatiitis B: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2013; 13(8): 1013-1017

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B

OBJECTIVES: The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-resistant chronic hepatitis B (CHB).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Evaluation on HBeAg conversion time when treating chronic hepatitis B patients with combination of lamivudine and traditional Chinese medicine

OBJECTIVE: To evaluate the effect of the combined use of traditional Chinese medicine and lamivudine (LMD) in treating chronic hepatitis B patients, and to follow the serological response for six months or longer.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: a meta-analysis

To determine whether adefovir (ADV) in combination with entecavir (ETV) is more effective than with lamivudine (LAM) in patients with lamivudine-resistant chronic HBV infection, electronic databases were searched through May 10th, 2013 to obtain relevant trials which met the inclusion criteria. Meta-analysis was performed on randomized controlled trials (RCTs) and non-randomized studies. Four trials containing a total of 323 patients were included. Serum HBV DNA reductions after 3 and 6 months of treatment in the ETV + ADV group were greater than that of LAM + ADV group (mean difference (MD) = 0.90, 95% confidence interval (CI): 0.74-1.07, P < 0.00001; MD = 0.81, 95% CI: 0.57-1.06, P < 0.00001). The rate of 6 months HBV DNA undetectability with ETV and ADV was higher than that of LAM and ADV (relative risk (RR) = 1.63, 95% CI: 1.14-2.34, P < 0.007). There were higher rates of serum ALT normalization than those in LAM + ADV group after 6 months of treatment (RR = 1.40, 95% CI: 1.11-1.77, P < 0.005). The ETV + ADV group had lower viral breakthrough and genotypic mutation rates than LAM + ADV group after 12 months of treatment (RR = 0.24, 95% CI: 0.10-0.58, P = 0.002). The combination of ETV plus ADV is a more effective rescue therapy than LAM add-on ADV in patients with LAM-resistant HBV.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Comparison of the efficacy of lamivudine plus adefovir versus entecavir in the treatment of lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis

BACKGROUND: Hepatitis B virus infection remains 1 of the major health threats worldwide. Currently, lamivudine plus adefovir combination therapy or entecavir monotherapy is usually used for the treatment of patients with lamivudine-resistant chronic hepatitis B (CHB). However, there are few systematic comparisons between the efficacy of lamivudine plus adefovir and the efficacy of entecavir in the treatment of these patients.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Antiretroviral regimens for patients with HIV who fail first‐line antiretroviral therapy

Highly active antiretroviral therapy (HAART) has greatly reduced the illness and deaths of HIV‐infected people worldwide. There are many options for first‐line antiretroviral therapy (ART), but second‐line therapy is necessary for people who fail the first‐line treatment. This review attempted to assess the best ART regimen for HIV‐infected people in low‐ and middle‐income countries following treatment failure; however, the review found limited studies addressing this topic. One randomised trial and one abstract of an observational study evaluated whether or not to maintain lamivudine in second‐line regimens; both suggested no difference in outcomes. There were no studies comparing boosted PI‐containing second‐line regimens in patients failing an NNRTI‐based first‐line regimen, nor any evaluating NRTI combinations after first‐line with non‐thymidine analog combinations. While such trials are difficult to conduct for a variety of reasons, randomised controlled trails comparing second‐line therapies are needed, especially in resource‐limited settings.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials

BACKGROUND: It has been demonstrated that only a minority of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) obtain a sustained response after either interferon (IFN) or nucleos(t)ide analogue monotherapy. Therefore, combination therapy of drugs with synergistic antiviral effects was proposed to have a sustained response in these patients. We compared the effect and safety of lamivudine monotherapy and its combination with IFN including conventional interferon (CON-IFN) and pegylated interferon (PEG-IFN) for HBeAg-negative CHB patients.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review

BACKGROUND: Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the treatment of chronic hepatitis B.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials

INTRODUCTION: Lamivudine and emtricitabine are considered equivalent by several guidelines, but evidence of comparable efficacy is conflicting.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Drugs for preventing hepatitis B recurrence after liver transplantation

Chronic hepatitis B is a very common infectious disease leading to chronic liver disease, affecting around 350 million people all over the world. Liver transplantation is often the only viable treatment option. Recurrence of hepatitis B virus (HBV) infection in the liver graft is one of the grave complications of liver transplantation, and to prevent it, hepatitis B immunoglobulin (HBIg) seem associated with improved survival. HBIg and/or antiviral drugs are given alone or in combination after liver transplantation. We attempted to identify the optimal preventive treatment option.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2010

Comparing initial antiretroviral regimens tenofovir or zidovudine as part of three‐drug combinations for treatment of HIV infection

The introduction of highly active antiretroviral therapy (ART) as treatment for HIV infection has greatly improved mortality and morbidity for adults and adolescents living with HIV around the world. Deciding which treatment regimen to begin for first‐line treatment in ART‐naïve patients, however, remains a significant challenge. Two commonly used medications are tenofovir (TDF) and zidovudine (AZT). The purpose of this review was to assess which of these two medications was the best for initial treatment for people living with HIV, and through our search we identified two randomised controlled trials. We did not find any critical difference between the two medications in regards to serious adverse events or virologic response, but did find that TDF is superior to AZT in terms of immunologic response and adherence and more frequent emergence of resistance. However, these two studies are not directly comparable because they used two related different drugs in addition to TDF and AZT. Future studies and recommendations should focus on specific toxicities and tolerability when comparing these two medications.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

HBV genotype b/c and response to lamivudine therapy: a systematic review

A number of nucleoside analogues such as lamivudine (LAM), actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology, and enhance the rate of hepatitis B e antigen (HBeAg) clearance. The responses to LAM therapy involve HBeAg clearance and HBV DNA conversion of negative. However, the associations between HBV genotype B/C and response to LAM therapy remain ambiguous. The aim of this meta-analysis is to determine more precise estimations of the relationship. All the publications on the associations between HBV genotype B/C and response to LAM (HBeAg clearance and HBV DNA conversion of negative) through June 2013 were collected. Relative risk (RR) with 95% confidence intervals (95% CI) was calculated in fixed or random model, I² was calculated to examine heterogeneity, and funnel plots were plotted to examine small study effects with Stata 11 software. Overall, for HBeAg clearance and genotype B/C, the RR (95% CI) was 1.27 (0.94-1.71), while for HBV DNA conversion of negative and genotype B/C, the RR (95% CI) was 1.07 (0.98-1.17). HBV genotype B/C shows no significance associations with response to lamivudine therapy (HBeAg clearance and HBV DNA conversion of negative).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

BACKGROUND: Reactivation of hepatitis B virus infection in asymptomatic hepatitis B surface antigen carriers undergoing chemotherapy or immunosuppressive therapy is a well-documented and potentially fatal complication. Data supporting the use of lamivudine for primary prophylaxis have emerged, but its use remains controversial and is not standardized.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis

OBJECTIVES: To evaluate efficacy of lamivudine in reducing in utero transmission of hepatitis B virus (HBV).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Systematic Reviews in PubMed

See all (276)...

Systematic Review Methods in PubMed

See all (2)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...